Postmarketing studies of drug efficacy: when must they be randomized? - Suppr | 超能文献

Postmarketing studies of drug efficacy: when must they be randomized?

作者信息

Strom B L, Miettinen O S, Melmon K L

出版信息

Clin Pharmacol Ther. 1983 Jul;34(1):1-7. doi: 10.1038/clpt.1983.119.

DOI:10.1038/clpt.1983.119

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Postmarketing studies of drug efficacy: when must they be randomized?

Clin Pharmacol Ther. 1983 Jul;34(1):1-7. doi: 10.1038/clpt.1983.119.

2

Postmarketing studies of drug efficacy.

Arch Intern Med. 1985 Oct;145(10):1791-4.

3

Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods.药物不良反应的发现。选定的IV期研究与自发报告方法的比较。

JAMA. 1983;249(16):2226-28. doi: 10.1001/jama.249.16.2226.

4

[Postmarketing surveillance of drugs].

Rev Prat. 1983 Jan 1;33(1-2):23-8.

5

Techniques of postmarketing surveillance. An overview.上市后监测技术。概述。

Med Toxicol. 1986 Jul-Aug;1(4):237-46. doi: 10.1007/BF03259840.

6

Postmarketing surveillance methodologies.

Drug Intell Clin Pharm. 1988 Jan;22(1):68-78. doi: 10.1177/106002808802200117.

7

The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance.

Clin Pharmacol Ther. 1985 Oct;38(4):359-64. doi: 10.1038/clpt.1985.188.

8

The epidemiological evaluation of drugs.

Acta Med Scand Suppl. 1984;683:23-7. doi: 10.1111/j.0954-6820.1984.tb08710.x.

9

Postmarketing follow-up: physicians have key role.上市后随访：医生发挥关键作用。

JAMA. 1985 Oct 25;254(16):2217.

10

What you should know about FDA-USP Drug Product Problem Reporting Program.

Pharm Times. 1986 Apr;52(4):101-4, 109.

引用本文的文献

1

Personalization of medicine requires better observational evidence.医学的个性化需要更好的观察性证据。

Clin Epidemiol. 2018 Oct 3;10:1391-1399. doi: 10.2147/CLEP.S167137. eCollection 2018.

2

Developments in post-marketing comparative effectiveness research.上市后比较效果研究的进展

Clin Pharmacol Ther. 2007 Aug;82(2):143-56. doi: 10.1038/sj.clpt.6100249. Epub 2007 Jun 6.

3

[Observational studies to evaluate the clinical effectiveness of drugs. Use of guide lists for their design, analysis, and interpretation].[评估药物临床疗效的观察性研究。使用指南清单进行设计、分析和解读]

Aten Primaria. 2005 Feb 28;35(3):156-62. doi: 10.1157/13071942.

4

Design issues for drug epidemiology.药物流行病学的设计问题

Br J Clin Pharmacol. 2000 Nov;50(5):419-25. doi: 10.1046/j.1365-2125.2000.00289.x.

5

Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.处方药的参考定价：探索血管紧张素转换酶抑制剂的等效性。

CMAJ. 1999 Aug 10;161(3):255-60.

6

Techniques of postmarketing surveillance. An overview.上市后监测技术。概述。

Med Toxicol. 1986 Jul-Aug;1(4):237-46. doi: 10.1007/BF03259840.

7

Is there a hierarchy of methods in clinical research?

Klin Wochenschr. 1989 May 15;67(10):515-7. doi: 10.1007/BF01719775.